NASDAQ$VCYT
Veracyte Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Veracyte's revenue increased by 16% to $34.5 million and genomic testing volume grew by 14% to 13,130 tests.
Veracyte announced a 16% increase in revenue to $34.5 million for the fourth quarter of 2020, with a 14% growth in genomic testing volume. The company is set to acquire Decipher Biosciences to expand its reach in cancer genomic diagnostics. Multiple new product launches are planned for 2021, including a noninvasive nasal swab test and Percepta Genomic Atlas in lung cancer.
- Total revenue increased by 16% to $34.5 million.
- Gross margin was 68%, an increase of 2 percentage points.
- Genomic testing and product volume increased by 14% to 13,130 tests.
- Net loss per common share was $0.14, compared to $0.15.
Headline financials
Revenue & EPS history
Veracyte · Revenue · Quarterly
$34.5M
Revenue by segment
Veracyte · $34.5M total across 3 segments · Q4 2020
- Testing Revenue$31.5M+10.3%91.2%
- Product Revenue$2.7M+192.1%7.8%
- Biopharmaceutical and Other$343K+37.2%1.0%
Forward guidance
Veracyte expects total combined revenue in 2021 to be approximately $190 million to $200 million, representing growth of approximately 65% over 2020 at the midpoint of the range, pending the completion of the acquisition of Decipher Biosciences, which is assumed to occur by April 1, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+1.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+5.4%
Avg return
30 days after
50%
23 / 46 earnings
Positive
+28.8%
Q2 2024
Best reaction
-22.4%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.9% | +20.4% | +47.7% | |
| Q4 2025 | +8.4% | -1.8% | -16.0% | |
| Q3 2025 | -9.4% | -7.3% | -3.1% | |
| Q1 2025 | +1.3% | -5.0% | -11.0% | |
| Q4 2024 | -15.0% | -11.7% | -21.0% | |
| Q3 2024 | +3.9% | +8.2% | +22.8% | |
| Q2 2024 | +28.8% | +39.4% | +41.8% | |
| Q1 2024 | -3.8% | +2.2% | +2.3% | |
| Q4 2023 | -9.6% | -3.7% | -14.1% | |
| Q3 2023 | -2.3% | -6.3% | +5.6% | |
| Q2 2023 | +7.9% | +1.5% | +2.2% | |
| Q1 2023 | +8.2% | +6.7% | +24.2% | |
| Q4 2022 | +5.3% | +6.6% | -3.3% | |
| Q3 2022 | +17.3% | +19.8% | +41.1% | |
| Q2 2022 | -3.0% | +8.1% | -23.3% | |
| Q1 2022 | +4.0% | -14.6% | -15.6% | |
| Q4 2021 | +4.1% | -8.1% | +6.8% | |
| Q3 2021 | -9.5% | -5.2% | -22.4% | |
| Q2 2021 | +13.0% | +13.1% | +21.0% | |
| Q1 2021 | -10.1% | -17.6% | -19.9% | |
| Q4 2020 | -6.5% | -15.5% | -30.4% | |
| Q3 2020 | +10.3% | +23.9% | +58.9% | |
| Q2 2020 | +18.2% | +6.7% | +9.4% | |
| Q1 2020 | -0.1% | -2.6% | -4.4% | |
| Q4 2019 | -2.3% | +3.7% | +3.3% | |
| Q3 2019 | -15.6% | -19.0% | -1.8% | |
| Q2 2019 | -2.8% | -13.8% | -7.3% | |
| Q1 2019 | +9.1% | +6.6% | +8.5% | |
| Q4 2018 | +9.1% | +2.5% | +20.1% | |
| Q3 2018 | +20.4% | +47.9% | +30.6% | |
| Q2 2018 | +8.6% | +4.0% | +15.6% | |
| Q1 2018 | -2.1% | +0.5% | +26.2% | |
| Q4 2017 | +1.0% | +0.3% | -6.7% | |
| Q3 2017 | -22.4% | -24.8% | -24.8% | |
| Q2 2017 | -2.1% | -1.3% | -4.8% | |
| Q1 2017 | -0.5% | -8.1% | -0.5% | |
| Q4 2016 | +12.0% | +17.8% | +18.5% | |
| Q3 2016 | -1.9% | +5.3% | +19.2% | |
| Q2 2016 | -0.2% | +1.2% | +14.4% | |
| Q1 2016 | +1.1% | — | — | |
| Q4 2015 | -8.8% | — | — | |
| Q3 2015 | -1.0% | — | — | |
| Q2 2015 | -7.9% | — | — | |
| Q1 2015 | +7.2% | — | — | |
| Q4 2014 | -10.9% | — | — | |
| Q2 2013 | +5.8% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro